Clinical Trial Update: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy [Phase 1]

View source ↗

Summary

Takeda-sponsored Phase 1 trial of Mezagitamab in adults with primary IgA nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Mezagitamab (mezagitamab)

Snippet

Sponsor: Takeda | Conditions: Kidney Disease, Glomerulonephritis | Phase 1 | Status: COMPLETED